ITP: Interventions Testing Program: Effects of various treatments on lifespan and related phenotypes in genetically heterogeneous mice (UM-HET3) (2004-2024)

Miller RA, Strong R, Korstanje R, Harrison DE, Rosenthal NA

     
The Interventions Testing Program (ITP, National Institute on Aging) is a multi-institutional study investigating treatments with the potential to extend lifespan and delay disease and dysfunction in heterogeneous populations of UM-HET3 mice. Such treatments include pharmaceuticals, nutraceuticals, foods, diets, dietary supplements, plant extracts, hormones, peptides, amino acids, chelators, redox agents, and other agents or mixtures of agents. The three ITP test sites (with abbreviations as used in these data) are:
  • The Jackson Laboratory (TJL)
  • University of Michigan at Ann Arbor (UM)
  • University of Texas Health Science Center (UT)

ITP1 downloads
Follow the links in the table below under "Compound's effect on lifespan" and "Other phenotypes" where you can download cohort specific results. • Download ITP1 supplementary file, ITP_C2020_Lifespan.xlsx    
• Download ITP1 supplementary file, ITP_C2018_Lifespan.xlsx    
• Download ITP1 supplementary file, ITP_C2019_Lifespan.xlsx    
Investigators Richard A Miller       University of Michigan,  Ann Arbor, MI
Randy Strong       University of Texas Health Science Center,  San Antonio, TX
Ron Korstanje       The Jackson Laboratory,  Bar Harbor, ME
David E Harrison       The Jackson Laboratory,  Bar Harbor, ME
Nadia A Rosenthal       The Jackson Laboratory,  Bar Harbor, ME
ContactRichard A Miller     millerr@umich.edu     Lab web site
Affiliated CenterNational Institute on Aging Interventions Testing Program (ITP)
AcknowledgementsFunding provided by NIH AG022303, AG022307, AG022308, AG066346
Project type Phenotype archive study
MPD identifiersITP1     MPD:508
Data changelog 5 updates/corrections.       Initial release date: 08/2024.
Formatted citation
Click above to copy-paste the entire citation for this MPD web page.
   


Study results by compound and year

Compound name and (abbreviation) Year
cohort
Dose in food Age at initiation Compound's
effect on lifespan*
Other phenotypes Ref#
16-a-hydroxyestriol (OH-Est) C2020 5 ppm 12 mo View survival analysis   New
males p = 0.0004
[19]
17-a-estradiol (17aE2) C2009 4.8 ppm 10 mo View survival analysis
males p = 0.0025
[8]
17-a-estradiol (17aE2) C2011 14 ppm 10 mo View survival analysis
males p < 0.0001
• body weight
• uterus weight (OVX)
[10]
17-a-estradiol (17aE2) C2016 14.4 ppm 16 or 20 mo View survival analysis
16 mo males p < 0.0001
20 mo males p = 0.0064
• body weight
[16]
17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (DMAG) C2015 30 ppm 6 mo View survival analysis [14]
2-(2-Hydroxyphenyl)benzoxazole (HBX) C2012 1 ppm 15 mo View survival analysis [12]
2,4-dinitrophenol (DNP) C2020 3 ppm 6 mo View survival analysis   New [19]
3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one (MIF098) C2016 240 ppm 8 mo View survival analysis • body weight
[16]
4-OH-a-phenyl-N-tert-butyl nitrone (4-OH-PBN) C2004 315 ppm 4 mo View survival analysis [2]
4-phenylbutyrate (PBA) C2019 1000 ppm 9 mo View survival analysis   New [18]
acarbose (ACA) C2009 1000 ppm 4 mo View survival analysis
males p < 0.0001
females p = 0.0048
[8]
acarbose (ACA) C2012 1000 ppm 16 mo View survival analysis
males p < 0.0001
[10]
acarbose (ACA) C2013 400, 1000, 2500 ppm 4 or 8 mo View survival analysis
400 ppm females p = 0.033
400 ppm males p < 0.0001
1000 ppm females p = 0.0027
1000 ppm males p < 0.0001
2500 ppm females p = 0.0061
2500 ppm males p < 0.0001
• body composition
• body weight
• fat pads
• grip strength
• grip duration
• pathology
• postprandial glucose
• rotarod
[12]
a-Ketoglutarate (AKG) C2020 20,000 ppm 18 mo View survival analysis   New [19]
aspirin (Asp) C2004 20 ppm 4 mo View survival analysis
males p = 0.0106
[2]
aspirin (Asp) C2014 60, 200 ppm 11 mo View survival analysis [13]
astaxanthin (Asta) C2019 4000 ppm 12 mo View survival analysis   New
males p = 0.003
[18]
b-guanidinopropionic acid (bGPA) C2015 3300 ppm 6 mo View survival analysis [14]
caffeic acid phenethyl ester (CAPE) C2005 30 and 300 ppm 4 mo View survival analysis [4]
canagliflozin (Cana) C2016 180 ppm 7 mo View survival analysis
males p < 0.0001
• body weight
[14]
canagliflozin (Cana) C2020 180 ppm 6 or 16 mo View survival analysis   New
males 6 mo p = 0.0209
males 16 mo p = 0.023
[19]
candesartan cilexetil (CC) C2016 30 ppm 7 mo View survival analysis • body weight
[16]
captopril (Capt) C2017 180 ppm 5 mo View survival analysis
females p = 0.002
males p = 0.001
[17]
curcumin (Cur) C2007 2000 ppm 4 mo View survival analysis [6]
dimethyl fumarate (DMF) C2019 120 ppm 9 or 16 mo View survival analysis   New [18]
enalapril (Enal) C2005 120 ppm 4 mo View survival analysis [4]
fisetin (Fis) C2018 600 ppm 20 mo (3 days on/11 days off) and 20 mo (continuous) View survival analysis   New [18]
fish oil (FO) C2010 15,000 and 50,000 ppm 9 mo View survival analysis • body weight
[10]
geranylgeranyl acetone (GGA) C2016 600 ppm 9 mo View survival analysis • body weight
[16]
glycine (Gly) C2014 80,000 ppm 9 mo View survival analysis
females p = 0.0167
males p = 0.0024
[13]
green tea extract (GTE) C2007 2000 ppm 4 mo View survival analysis [6]
Hydralazine (HYD) C2020 30 ppm 6 or 16 mo View survival analysis   New [19]
INT-767 FXR/TGR5 agonist (INT-767) C2012 180 ppm 10 mo View survival analysis [12]
inulin (Inu) C2014 600 ppm 11 mo View survival analysis [13]
L-leucine (Leu) C2017 40,000 ppm 5 mo View survival analysis [17]
meclizine (Mec) C2019 800 ppm 12 mo View survival analysis   New
males p = 0.027
[18]
medium-chain triglyceride oil (MCTO) C2007 60,000 ppm 4 mo View survival analysis [6]
metformin (Met) C2011 1000 ppm 9 mo View survival analysis • body weight
[10]
metformin and rapamycin (MetRapa) C2011 Met:1000 ppm and Rapa:14 ppm 9 mo View survival analysis
both sexes p < 0.0001
• body weight
[10]
methylene blue (MB) C2009 28 ppm 4 mo View survival analysis [8]
minocycline (Min) C2015 300 ppm 6 mo View survival analysis [14]
MitoQ (MitoQ) C2015 100 ppm 7 mo View survival analysis [14]
mycophenolic acid (MPA) C2019 6.7 ppm 9 mo View survival analysis   New [18]
Nebivolol (NEBI) C2020 60 ppm 6 mo View survival analysis   New [19]
nicotinamide riboside (NR) C2016 1000 ppm 8 mo View survival analysis • body weight
[16]
nitroflurbiprofen (NFP) C2004 200 ppm 4 mo View survival analysis [2]
nordihydroguaiaretic acid (NDGA) C2004 2500 ppm 9 mo View survival analysis
males p = 0.0006
[2]
nordihydroguaiaretic acid (NDGA) C2010 800, 2500, 5000 ppm 6 mo View survival analysis
800 ppm males p = 0.0228
2500 ppm males p = 0.0147
5000 ppm males p = 0.0028
• body weight
• grip strength
• grip duration
• rotarod
[10]
oxaloacetic acid (OAA) C2007 2200 ppm 4 mo View survival analysis [6]
PB125 (PB125) C2017 see publication 5 mo View survival analysis [17]
Protandim (Prot) C2011 600 ppm then 1200 ppm 10 mo then 17 mo View survival analysis
males p = 0.0095
• body weight
[10]
rapamycin (Rapa) C2005 14 ppm 20 mo View survival analysis
both sexes p < 0.0001
[4]
rapamycin (Rapa) C2006 14 ppm 9 mo View survival analysis
both sexes p < 0.0001
[5]
rapamycin (Rapa) C2009 4.7, 14, and 42 ppm 9 mo View survival analysis
4.7 ppm females p < 0.0001
14 ppm females p < 0.0001
14 ppm males p = 0.0034
42 ppm both sexes p < 0.0001
[7]
rapamycin (Rapa) C2015 42 ppm 20 mo (stop at 23) View survival analysis
males p = 0.0243
[15]
rapamycin (Rapa) C2015 42 ppm 20 mo (but every other month) View survival analysis
females = 0.0001
males p = 0.0019
[15]
rapamycin (Rapa) C2015 42 ppm 20 mo View survival analysis
females p < 0.0001
males p = 0.0007
[15]
rapamycin and acarbose (RaAc) C2017 Rapa: 14.7 ppm and ACA: 1000 ppm 9 or 16 mo View survival analysis
9 mo females p < 0.0001
9 mo males p < 0.0001
16 mo females p < 0.0001
16 mo males p < 0.0001
[17]
resveratrol (Res) C2006 300 and 1200 ppm 12 mo View survival analysis [5]
resveratrol (Res) C2007 300 ppm 4 mo View survival analysis [6]
(R/S)-1,3-butanediol (BD) C2017 100,000 ppm 6 mo View survival analysis
females p = 0.0395
[17]
SG1002 (SG1002) C2018 240 ppm 18 mo View survival analysis   New [18]
SG1002 (SG1002) C2019 240 ppm 6 mo View survival analysis   New [18]
simvastatin (Sim) C2006 12 and 120 ppm 10 mo View survival analysis [5]
Sodium thiosulfate (THIO) C2020 10,000 ppm 6 mo View survival analysis   New [19]
sulindac (Sul) C2017 5 ppm 5 mo View survival analysis [17]
syringaresinol (Syr) C2017 300 ppm 5 mo View survival analysis [17]
TM5441 (TM5441) C2014 60 ppm 11 mo View survival analysis [13]
ursodeoxycholic acid (UDCA) C2011 5000 ppm 5 mo View survival analysis • body weight
[10]
ursolic acid (UA) C2013 2000 ppm 10 mo View survival analysis [12]

* Log-rank test p-value on treated vs. control, shown when p ≤ 0.05 for each sex separately. Statistical definitions



References   (chronological)

1.   Miller RA, Harrison DE, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Strong R. An Aging Interventions Testing Program: study design and interim report. Aging Cell. 2007 Aug;6(4):565-75. Epub 2007 Jun 18.   PubMed 17578509  

2.   Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Harrison DE. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell. 2008 Oct;7(5):641-50. doi: 10.1111/j.1474-9726.2008.00414.x.   PubMed 18631321     FullText

3.   Nadon NL, Strong R, Miller RA, Nelson J, Javors M, Sharp ZD, Peralba JM, Harrison DE. Design of aging intervention studies: the NIA interventions testing program. Age (Dordr). 2008 Dec;30(4):187-99. doi: 10.1007/s11357-008-9048-Epub 2008 Apr 18.   PubMed 19424842     FullText

4.   Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009 Jul 16;460(7253):392-5. doi: 10.1038/nature0822Epub 2009 Jul 8.   PubMed 19587680     FullText

5.   Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011 Feb;66(2):191-20doi: 10.1093/gerona/glq178. Epub 2010 Oct 25.   PubMed 20974732     FullText

6.   Strong R, Miller RA, Astle CM, Baur JA, de Cabo R, Fernandez E, Guo W, Javors M, Kirkland JL, Nelson JF, Sinclair DA, Teter B, Williams D, Zaveri N, Nadon NL, Harrison DE. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):6-16. doi: 10.1093/gerona/gls070. Epub 2012 Mar 26.   PubMed 22451473     FullText

7.   Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA, Miller RA. Rapamycin slows aging in mice. Aging Cell. 2012 Aug;11(4):675-82. doi: 10.1111/j.1474-9726.2012.00832.x. Epub 2012 Jun 4.   PubMed 22587563     FullText

8.   Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, Nelson JF, Pletcher S, Simpkins JW, Smith D, Wilkinson JE, Miller RA. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014 Apr;13(2):273-82. doi: 10.1111/acel.12170. Epub 2013 Nov 19.   PubMed 24245565     FullText

9.   Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Sharp ZD, Van Roekel S, Winkleman L, Strong R. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014 Jun;13(3):468-77. doi: 10.1111/acel.12194. Epub 2014 Feb 9.   PubMed 24341993     FullText

10.   Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016 Oct;15(5):872-84. doi: 10.1111/acel.12496. Epub 2016 Jun 16.   PubMed 27312235  

11.   Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model. EBioMedicine. 2017 Jul;21:3-4. doi: 10.1016/j.ebiom.2016.11.038. Epub 2016 Dec 2.   PubMed 27923560  

12.   Harrison DE, Strong R, Alavez S, Astle CM, DiGiovanni J, Fernandez E, Flurkey K, Garratt M, Gelfond JAL, Javors MA, Levi M, Lithgow GJ, Macchiarini F, Nelson JF, Sukoff Rizzo SJ, Slaga TJ, Stearns T, Wilkinson JE, Miller RA. Acarbose improves health and lifespan in aging HET3 mice. Aging Cell. 2019 Apr;18(2):e12898. doi: 10.1111/acel.12898. Epub 2019 Jan 27.   PubMed 30688027  

13.   Miller RA, Harrison DE, Astle CM, Bogue MA, Brind J, Fernandez E, Flurkey K, Javors M, Ladiges W, Leeuwenburgh C, Macchiarini F, Nelson J, Ryazanov AG, Snyder J, Stearns TM, Vaughan DE, Strong R. Glycine supplementation extends lifespan of male and female mice. Aging Cell. 2019 Jun;18(3):e12953. doi: 10.1111/acel.12953. Epub 2019 Mar 27.   PubMed 30916479     FullText

14.   Miller RA, Harrison DE, Allison DB, Bogue M, Debarba L, Diaz V, Fernandez E, Galecki A, Garvey WT, Jayarathne H, Kumar N, Javors MA, Ladiges WC, Macchiarini F, Nelson J, Reifsnyder P, Rosenthal NA, Sadagurski M, Salmon AB, Smith DL Jr, Snyder JM, Lombard DB, Strong R. Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. pii: 140019. doi: 10.1172/jci.insight.140019.   PubMed 32990681     FullText

15.   Strong R, Miller RA, Bogue M, Fernandez E, Javors MA, Libert S, Marinez PA, Murphy MP, Musi N, Nelson JF, Petrascheck M, Reifsnyder P, Richardson A, Salmon AB, Macchiarini F, Harrison DE. Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects. Aging Cell. 2020 Nov;19(11):e13269. doi: 10.1111/acel.13269. Epub 2020 Nov 4.   PubMed 33145977     FullText

16.   Harrison DE, Strong R, Reifsnyder P, Kumar N, Fernandez E, Flurkey K, Javors MA, Lopez-Cruzan M, Macchiarini F, Nelson JF, Bitto A, Sindler AL, Cortopassi G, Kavanagh K, Leng L, Bucala R, Rosenthal N, Salmon A, Stearns TM, Bogue M, Miller RA. 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex. Aging Cell. 2021 May;20(5):e13328. doi: 10.1111/acel.13328. Epub 2021 Mar 31.   PubMed 33788371     FullText

17.   Strong R, Miller RA, Cheng CJ, Nelson JF, Gelfond J, Allani SK, Diaz V, Dorigatti AO, Dorigatti J, Fernandez E, Galecki A, Ginsburg B, Hamilton KL, Javors MA, Kornfeld K, Kaeberlein M, Kumar S, Lombard DB, Lopez-Cruzan M, Miller BF, Rabinovitch P, Reifsnyder P, Rosenthal NA, Bogue MA, Salmon AB, Suh Y, Verdin E, Weissbach H, Newman J, Maccchiarini F, Harrison DE. Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice. Aging Cell. doi: 10.1111/acel.13724.   PubMed 36179270  

18.   Harrison DE, Strong R, Reifsnyder P, Rosenthal N, Korstanje R, Fernandez E, Flurkey K, Ginsburg BC, Murrell MD, Javors MA, Lopez-Cruzan M, Nelson JF, Willcox BJ, Allsopp R, Watumull DM, Watumull DG, Cortopassi G, Kirkland JL, Tchkonia T, Choi YG, Yousefzadeh MJ, Robbins PD, Mitchell JR, Acar M, Sarnoski EA, Bene MR, Salmon A, Kumar N, Miller RA. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. Geroscience. 2024 Feb;46(1):795-816. doi: 10.1007/s11357-023-01011-0. Epub 2023 Dec 2.   PubMed 38041783     FullText

19.   Miller RA, Harrison DE, Cortopassi GA, Dehghan I, Fernandez E, Garratt M, Geisler JG, Ginsburg BC, Han ML, Kaczorowski CC, Kumar N, Leiser SF, Lopez-Cruzan M, Milne G, Mitchell JR, Nelson JF, Reifsnyder PC, Salmon AB, Korstanje R, Rosenthal N, Strong R. Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. Geroscience. 2024 Oct;46(5):4657-4670. doi: 10.1007/s11357-024-01176-2. Epub 2024 May 16.   PubMed 38753230     FullText